13F reference period
Q2 2026
Security Snapshot
Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX) Institutional Ownership
CUSIP: 47103J105
13F Institutional Holders and Ownership History from Q2 2021 to Q3 2026
Institutions Reporting
193
Shares (Excl. Options)
60.79M
Full value: 60,787,798 · shares · 30 Jun 2026Price
$15.36
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- JANX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 60,787,798
- Total 13F value
- $933,370,141
- Portfolio coverage rank
- 0%
- Share change
- +5,121,199
- Value change
- +$84,981,604
- Number of holders
- 193
- Shares outstanding
- 60,419,303
- SEC-reported price per share
- $17.28
- Insider filing price
- $17.28
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 47103J105.
- 193 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 188 to 193 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$827.82M
Full value: $827,823,706 · USD · 31 Mar 2026.$933.37M
Full value: $933,370,141 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 193 institutions filings for Q2 2026.
Security key
47103J105
13F reference period
Q2 2026
13F holders
193
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
JANX full holder history
Janux Therapeutics, Inc. SEC filings
Janux Therapeutics, Inc. company facts
Janux Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 47103J105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
JANX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | $383,922,060 | 11,971,377 | RA Capital Management, L.P. | 06 Mar 2025 | |||
| BlackRock, Inc. | 6.7% | +17% | $62,952,300 | +$11,562,900 | 4,098,457 | +23% | BlackRock, Inc. | 30 Jun 2026 |
| Prosight Management, LP | 5.3% | $43,569,636 | 3,157,220 | W. Lawrence Hawkins | 03 Feb 2026 | |||
| Paradigm Biocapital Advisors LP | 4.9% | -18% | $73,444,489 | -$14,982,559 | 2,920,258 | -17% | Paradigm BioCapital Advisors LP | 30 Jun 2025 |
| FMR LLC | 4.2% | -27% | $35,246,558 | -$13,575,574 | 2,535,724 | -28% | FMR LLC | 31 Mar 2026 |
| Adage Capital Management, L.P. | 4.3% | -21% | $63,503,750 | -$13,499,262 | 2,525,000 | -18% | Adage Capital Management, L.P. | 30 Jun 2025 |
| STATE STREET CORP | 4.1% | -38% | $34,249,836 | -$19,320,083 | 2,464,017 | -36% | STATE STREET CORPORATION | 31 Mar 2026 |
| Point72 Asset Management, L.P. | 3.3% | -34% | $32,200,468 | -$17,376,140 | 1,993,837 | -35% | Point72 Asset Management, L.P. | 30 Jun 2026 |
| Janus Henderson Group Ltd. | 0.3% | -94% | $2,781,498 | -$64,990,507 | 172,229 | -96% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
As of 30 Jun 2026,
193
institutional investors reported holding
shares of
Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX).
This represents
101%
of the company’s total
outstanding shares.
60.79M
Full value: 60,787,798 · shares · 30 Jun 202660.42M
Full value: 60,419,303 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
84%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 19% | 11,189,693 | 0% | 1.5% | $171,873,684 |
| BlackRock, Inc. | 10% | 6,134,667 | +13% | 0% | $94,228,481 |
| Prosight Management, LP | 6.3% | 3,804,481 | +7.2% | 10% | $58,436,828 |
| STATE STREET CORP | 5% | 3,004,899 | +22% | 0% | $46,155,249 |
| FMR LLC | 4% | 2,412,825 | -4.8% | 0% | $37,060,986 |
| FEDERATED HERMES, INC. | 3.9% | 2,352,927 | +4241% | 0.05% | $36,140,959 |
| Point72 Asset Management, L.P. | 3.3% | 1,993,837 | +72% | 0.05% | $30,625,336 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,857,351 | +2.5% | 0% | $28,528,911 |
| TCG Crossover Management, LLC | 3% | 1,789,617 | 0% | 0.66% | $27,488,517 |
| Alyeska Investment Group, L.P. | 2.7% | 1,647,140 | +2.9% | 0.07% | $25,300,070 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.5% | 1,507,360 | -5.7% | 0% | $23,153,049 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2% | 1,330,710 | +3.1% | 0% | $20,439,706 |
| TWO SIGMA INVESTMENTS, LP | 2% | 1,207,250 | +940% | 0.01% | $18,543,360 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,204,150 | +5% | 0% | $18,499,798 |
| CITADEL ADVISORS LLC | 2% | 1,200,737 | +241% | 0.01% | $18,443,321 |
| ALGERT GLOBAL LLC | 1.8% | 1,110,889 | +151% | 0.2% | $17,063,255 |
| D. E. Shaw & Co., Inc. | 1.8% | 1,096,509 | +1014% | 0.01% | $16,842,378 |
| GOLDMAN SACHS GROUP INC | 1.6% | 952,675 | +58% | 0% | $14,633,088 |
| BANK OF AMERICA CORP /DE/ | 1.5% | 910,460 | +14% | 0% | $13,984,665 |
| MORGAN STANLEY | 1.4% | 836,966 | +19% | 0% | $12,855,801 |
| Nantahala Capital Management, LLC | 1.3% | 809,914 | 0% | 0.75% | $12,440,279 |
| Qube Research & Technologies Ltd | 1.2% | 702,057 | +256% | 0.01% | $10,783,596 |
| Squarepoint Ops LLC | 0.88% | 532,321 | -12% | 0.02% | $8,176,451 |
| ORBIMED ADVISORS LLC | 0.87% | 524,700 | -47% | 0.15% | $8,059,392 |
| MILLENNIUM MANAGEMENT LLC | 0.84% | 504,544 | +30% | 0.01% | $7,749,796 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Headline period
Q2 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 306,743 | $5,295,138 | -$1,577,054 | $17.28 | 25 |
| 2026 Q2 | 60,787,798 | $933,370,141 | +$84,981,604 | $15.36 | 193 |
| 2026 Q1 | 59,586,416 | $827,823,706 | -$45,211,811 | $13.90 | 188 |
| 2025 Q4 | 62,149,272 | $857,685,977 | -$103,940,615 | $13.80 | 173 |
| 2025 Q3 | 65,065,945 | $1,590,036,358 | -$3,819,977 | $24.44 | 170 |
| 2025 Q2 | 65,389,958 | $1,510,522,459 | -$28,053,981 | $23.10 | 169 |
| 2025 Q1 | 66,482,175 | $1,805,570,973 | -$17,647,630 | $27.00 | 179 |
| 2024 Q4 | 64,089,510 | $3,430,809,553 | +$1,001,839,547 | $53.54 | 213 |
| 2024 Q3 | 45,621,730 | $2,072,353,785 | +$42,332,014 | $45.43 | 158 |
| 2024 Q2 | 44,723,442 | $1,873,142,325 | +$107,659,314 | $41.89 | 153 |
| 2024 Q1 | 42,327,541 | $1,593,608,078 | +$334,250,630 | $37.65 | 118 |
| 2023 Q4 | 33,501,695 | $359,539,970 | -$17,204,195 | $10.73 | 64 |
| 2023 Q3 | 35,112,124 | $353,984,587 | +$45,518,472 | $10.08 | 57 |
| 2023 Q2 | 30,508,831 | $362,117,070 | -$408,523 | $11.87 | 54 |
| 2023 Q1 | 30,541,873 | $369,527,936 | +$18,629,245 | $12.10 | 48 |
| 2022 Q4 | 28,954,042 | $381,308,644 | -$7,758,264 | $13.17 | 49 |
| 2022 Q3 | 29,548,436 | $400,093,845 | +$8,918,649 | $13.54 | 45 |
| 2022 Q2 | 28,911,820 | $352,963,471 | +$6,297,905 | $12.21 | 43 |
| 2022 Q1 | 28,388,419 | $407,113,023 | +$11,406,319 | $14.34 | 46 |
| 2021 Q4 | 27,496,946 | $541,627,745 | +$19,103,067 | $19.73 | 46 |
| 2021 Q3 | 26,499,088 | $571,208,440 | +$35,499,490 | $21.63 | 44 |
| 2021 Q2 | 24,743,225 | $614,460,000 | +$614,460,000 | $24.95 | 29 |